Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism
From BugSigDB
Jump to:navigation, search
Study information
-
Quality control
- Retracted paper
- Contamination issues suspected
- Batch effect issues suspected
- Uncontrolled confounding suspected
- Results are suspect (various reasons)
- Tags applied
study design
Citation
PMID PubMed identifier for scientific articles.
DOI Digital object identifier for electronic documents.
URI
Authors
Barichella M, Severgnini M, Cilia R, Cassani E, Bolliri C, Caronni S, Ferri V, Cancello R, Ceccarani C, Faierman S, Pinelli G, De Bellis G, Zecca L, Cereda E, Consolandi C, Pezzoli G
Journal
Movement disorders : official journal of the Movement Disorder Society
Year
2019
Keywords:
MSA, PD, PSP, Parkinson-s disease, clinical features, gut-brain axis, multiple system atrophy, progressive supranuclear palsy
BACKGROUND: Although several studies have suggested that abnormalities in gut microbiota may play a critical role in the pathogenesis of PD, data are still extremely heterogeneous. METHODS: 16S gene ribosomal RNA sequencing was performed on fecal samples of 350 individuals, subdivided into idiopathic PD (n = 193, of whom 39 were drug naïve) stratified by disease duration, PSP (n = 22), MSA (n = 22), and healthy controls (HC; n = 113). Several confounders were taken into account, including dietary habits. RESULTS: Despite the fact that unadjusted comparison of PD and HC showed several differences in relative taxa abundances, the significant results were greatly reduced after adjusting for confounders. Although most of these differences were associated with disease duration, lower abundance in Lachnospiraceae was the only difference between de novo PD and HC (remaining lower across almost all PD duration strata). Decreased Lachnospiraceae and increased Lactobacillaceae and Christensenellaceae were associated with a worse clinical profile, including higher frequencies of cognitive impairment, gait disturbances, and postural instability. When compared with HC, MSA and PSP patients shared the changes in PD, with a few exceptions: in MSA, Lachnospiraceae were not lower, and Prevotellaceae were reduced; in PSP, Lactobacillaceae were similar, and Streptococcaceae were reduced. CONCLUSIONS: Gut microbiota may be an environmental modulator of the pathogenesis of PD and contribute to the interindividual variability of clinical features. Data are influenced by PD duration and several confounders that need to be taken into account in future studies. Prospective studies in de novo PD patients are needed to elucidate the net effect of dysbiosis on the progression of the disease. © 2018 International Parkinson and Movement Disorder Society.
Experiment 1
Reviewed Marked as Reviewed by Fatima on 2021/10/20
Subjects
- Location of subjects
- Italy
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Parkinson's disease IDIOPATHIC PARKINSON DIS,Idiopathic Parkinson Disease,Idiopathic Parkinson's Disease,IDIOPATHIC PARKINSONS DIS,Idiopathic PD,LEWY BODY PARKINSON DIS,Lewy Body Parkinson Disease,Lewy Body Parkinson's Disease,Paralysis agitans,paralysis agitans,PARKINSON DIS,PARKINSON DIS IDIOPATHIC,Parkinson disease,Parkinson Disease, Idiopathic,Parkinson syndrome,Parkinson's,Parkinson's disease,Parkinson's disease (disorder),Parkinson's disease NOS,Parkinson's disease NOS (disorder),Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinson's syndrome,Parkinsonian disorder,Parkinsonism, Primary,Parkinsons,PARKINSONS DIS,PARKINSONS DIS IDIOPATHIC,PARKINSONS DIS LEWY BODY,Parkinsons disease,Primary Parkinsonism,parkinson's disease
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- healthy controls without any form of Parkinson's Disease
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- patients with idiopathic parkinson's disease
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients with idiopathic parkinson's disease with stage diagnosed according to UK Brain Bank Criteria(1996)
- Group 0 sample size Number of subjects in the control (unexposed) group
- 113
- Group 1 sample size Number of subjects in the case (exposed) group
- 193
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- 1 month
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- V3-V4
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Illumina
Statistical Analysis
- Statistical test
- Negative Binomial Regression
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- Matched on Factors on which subjects have been matched on in a case-control study
- age, body mass index, geographic area
- Confounders controlled for Confounding factors that have been accounted for by stratification or model adjustment
- age, alcohol drinking, breast feeding, sex, smoking status, constipation, Confounders controlled for: "use of catechol-O-methyltransferase inhibitors" is not in the list (abnormal glucose tolerance, acetaldehyde, acute graft vs. host disease, acute lymphoblastic leukemia, acute myeloid leukemia, adenoma, age, AIDS, alcohol consumption measurement, alcohol drinking, ...) of allowed values.use of catechol-O-methyltransferase inhibitors, Confounders controlled for: "genetic status (recessive)" is not in the list (abnormal glucose tolerance, acetaldehyde, acute graft vs. host disease, acute lymphoblastic leukemia, acute myeloid leukemia, adenoma, age, AIDS, alcohol consumption measurement, alcohol drinking, ...) of allowed values.genetic status (recessive), Confounders controlled for: "protein intake" is not in the list (abnormal glucose tolerance, acetaldehyde, acute graft vs. host disease, acute lymphoblastic leukemia, acute myeloid leukemia, adenoma, age, AIDS, alcohol consumption measurement, alcohol drinking, ...) of allowed values.protein intake, Confounders controlled for: "animal vegetal protein ratio" is not in the list (abnormal glucose tolerance, acetaldehyde, acute graft vs. host disease, acute lymphoblastic leukemia, acute myeloid leukemia, adenoma, age, AIDS, alcohol consumption measurement, alcohol drinking, ...) of allowed values.animal vegetal protein ratio, Confounders controlled for: "fibers intake" is not in the list (abnormal glucose tolerance, acetaldehyde, acute graft vs. host disease, acute lymphoblastic leukemia, acute myeloid leukemia, adenoma, age, AIDS, alcohol consumption measurement, alcohol drinking, ...) of allowed values.fibers intake, Confounders controlled for: "insoluble-soluble fiber ratio" is not in the list (abnormal glucose tolerance, acetaldehyde, acute graft vs. host disease, acute lymphoblastic leukemia, acute myeloid leukemia, adenoma, age, AIDS, alcohol consumption measurement, alcohol drinking, ...) of allowed values.insoluble-soluble fiber ratio, Confounders controlled for: "water intake [mL/day]" is not in the list (abnormal glucose tolerance, acetaldehyde, acute graft vs. host disease, acute lymphoblastic leukemia, acute myeloid leukemia, adenoma, age, AIDS, alcohol consumption measurement, alcohol drinking, ...) of allowed values.water intake [mL/day], Confounders controlled for: "coffee intake" is not in the list (abnormal glucose tolerance, acetaldehyde, acute graft vs. host disease, acute lymphoblastic leukemia, acute myeloid leukemia, adenoma, age, AIDS, alcohol consumption measurement, alcohol drinking, ...) of allowed values.coffee intake
Alpha Diversity
- Chao1 Abundance-based estimator of species richness
- increased
- Richness Number of species
- increased
Signature 1
Reviewed Marked as Reviewed by Atrayees on 2023-7-12
Source: Supplementary table 3, Signature 1 is for increased abundance in those with Parkinson's
Description: Analysis of relative taxa abundance in controls and different disease groups.
Abundance in Group 1: increased abundance in patients with idiopathic parkinson's disease
Signature 2
Reviewed Marked as Reviewed by Atrayees on 2023-7-12
Source: Supplementary table 3,
Description: Analysis of relative taxa abundance in controls and different disease groups.
Abundance in Group 1: decreased abundance in patients with idiopathic parkinson's disease
| NCBI | Quality Control | Links |
|---|---|---|
| Lachnospiraceae | ||
| Roseburia | ||
| Oscillospiraceae | ||
| Bacillota | ||
| Faecalibacterium |
Experiment 2
Reviewed Marked as Reviewed by Atrayees on 2023-7-12
Differences from previous experiment shown
Subjects
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- the trend over Parkinson's disease progression
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients with idiopathic Parkinson's disease with stage diagnosed according to UK Brain Bank Criteria(1996)
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- Not specified
Lab analysis
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Confounders controlled for Confounding factors that have been accounted for by stratification or model adjustment
- age, breast feeding, smoking status, constipation, Confounders controlled for: "use of catechol-O-methyltransferase inhibitors" is not in the list (abnormal glucose tolerance, acetaldehyde, acute graft vs. host disease, acute lymphoblastic leukemia, acute myeloid leukemia, adenoma, age, AIDS, alcohol consumption measurement, alcohol drinking, ...) of allowed values.use of catechol-O-methyltransferase inhibitors, Confounders controlled for: "genetic status (recessive)" is not in the list (abnormal glucose tolerance, acetaldehyde, acute graft vs. host disease, acute lymphoblastic leukemia, acute myeloid leukemia, adenoma, age, AIDS, alcohol consumption measurement, alcohol drinking, ...) of allowed values.genetic status (recessive), Confounders controlled for: "gender" is not in the list (abnormal glucose tolerance, acetaldehyde, acute graft vs. host disease, acute lymphoblastic leukemia, acute myeloid leukemia, adenoma, age, AIDS, alcohol consumption measurement, alcohol drinking, ...) of allowed values.gender, Confounders controlled for: "protein intake" is not in the list (abnormal glucose tolerance, acetaldehyde, acute graft vs. host disease, acute lymphoblastic leukemia, acute myeloid leukemia, adenoma, age, AIDS, alcohol consumption measurement, alcohol drinking, ...) of allowed values.protein intake, Confounders controlled for: "animal vegetal protein ratio" is not in the list (abnormal glucose tolerance, acetaldehyde, acute graft vs. host disease, acute lymphoblastic leukemia, acute myeloid leukemia, adenoma, age, AIDS, alcohol consumption measurement, alcohol drinking, ...) of allowed values.animal vegetal protein ratio, Confounders controlled for: "alcohol intake" is not in the list (abnormal glucose tolerance, acetaldehyde, acute graft vs. host disease, acute lymphoblastic leukemia, acute myeloid leukemia, adenoma, age, AIDS, alcohol consumption measurement, alcohol drinking, ...) of allowed values.alcohol intake, Confounders controlled for: "fibers intake" is not in the list (abnormal glucose tolerance, acetaldehyde, acute graft vs. host disease, acute lymphoblastic leukemia, acute myeloid leukemia, adenoma, age, AIDS, alcohol consumption measurement, alcohol drinking, ...) of allowed values.fibers intake, Confounders controlled for: "insoluble-soluble fiber ratio" is not in the list (abnormal glucose tolerance, acetaldehyde, acute graft vs. host disease, acute lymphoblastic leukemia, acute myeloid leukemia, adenoma, age, AIDS, alcohol consumption measurement, alcohol drinking, ...) of allowed values.insoluble-soluble fiber ratio, Confounders controlled for: "water intake [mL/day]" is not in the list (abnormal glucose tolerance, acetaldehyde, acute graft vs. host disease, acute lymphoblastic leukemia, acute myeloid leukemia, adenoma, age, AIDS, alcohol consumption measurement, alcohol drinking, ...) of allowed values.water intake [mL/day], Confounders controlled for: "coffee intake" is not in the list (abnormal glucose tolerance, acetaldehyde, acute graft vs. host disease, acute lymphoblastic leukemia, acute myeloid leukemia, adenoma, age, AIDS, alcohol consumption measurement, alcohol drinking, ...) of allowed values.coffee intake, Confounders controlled for: "use of protein pump inhibitors" is not in the list (abnormal glucose tolerance, acetaldehyde, acute graft vs. host disease, acute lymphoblastic leukemia, acute myeloid leukemia, adenoma, age, AIDS, alcohol consumption measurement, alcohol drinking, ...) of allowed values.use of protein pump inhibitors
Signature 1
Reviewed Marked as Reviewed by Atrayees on 2023-7-12
Source: Supplementary table 4, Signature 1 is for increased taxa abundance in different groups of Parkinson's disease patients.
Description: Analysis of relative taxa abundance in different groups of Parkinson’s disease patients.
Abundance in Group 1: increased abundance in the trend over Parkinson's disease progression
| NCBI | Quality Control | Links |
|---|---|---|
| Akkermansia | ||
| Lactobacillaceae | ||
| Lactobacillus | ||
| Verrucomicrobiota | ||
| Verrucomicrobiaceae |
Revision editor(s): Fcuevas3
Signature 2
Reviewed Marked as Reviewed by Atrayees on 2023-7-12
Source: Supplementary table 4, Signature 2 is for decreased taxa abundance in different groups of Parkinson's disease patients.
Description: Analysis of relative taxa abundance in different groups of Parkinson’s disease patients.
Abundance in Group 1: decreased abundance in the trend over Parkinson's disease progression
| NCBI | Quality Control | Links |
|---|---|---|
| Lachnospiraceae |
Experiment 3
Reviewed Marked as Reviewed by Atrayees on 2023-7-12
Differences from previous experiment shown
Subjects
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- patients with MSA(multiple system atrophy) disease
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients diagnosed with synucleinopathy multiple system atrophy (MSA)
- Group 1 sample size Number of subjects in the case (exposed) group
- 22
Lab analysis
Statistical Analysis
- Confounders controlled for Confounding factors that have been accounted for by stratification or model adjustment
- age, alcohol drinking, breast feeding, sex, smoking status, constipation, Confounders controlled for: "use of catechol-O-methyltransferase inhibitors" is not in the list (abnormal glucose tolerance, acetaldehyde, acute graft vs. host disease, acute lymphoblastic leukemia, acute myeloid leukemia, adenoma, age, AIDS, alcohol consumption measurement, alcohol drinking, ...) of allowed values.use of catechol-O-methyltransferase inhibitors, Confounders controlled for: "genetic status (recessive)" is not in the list (abnormal glucose tolerance, acetaldehyde, acute graft vs. host disease, acute lymphoblastic leukemia, acute myeloid leukemia, adenoma, age, AIDS, alcohol consumption measurement, alcohol drinking, ...) of allowed values.genetic status (recessive), Confounders controlled for: "protein intake" is not in the list (abnormal glucose tolerance, acetaldehyde, acute graft vs. host disease, acute lymphoblastic leukemia, acute myeloid leukemia, adenoma, age, AIDS, alcohol consumption measurement, alcohol drinking, ...) of allowed values.protein intake, Confounders controlled for: "animal vegetal protein ratio" is not in the list (abnormal glucose tolerance, acetaldehyde, acute graft vs. host disease, acute lymphoblastic leukemia, acute myeloid leukemia, adenoma, age, AIDS, alcohol consumption measurement, alcohol drinking, ...) of allowed values.animal vegetal protein ratio, Confounders controlled for: "fibers intake" is not in the list (abnormal glucose tolerance, acetaldehyde, acute graft vs. host disease, acute lymphoblastic leukemia, acute myeloid leukemia, adenoma, age, AIDS, alcohol consumption measurement, alcohol drinking, ...) of allowed values.fibers intake, Confounders controlled for: "insoluble-soluble fiber ratio" is not in the list (abnormal glucose tolerance, acetaldehyde, acute graft vs. host disease, acute lymphoblastic leukemia, acute myeloid leukemia, adenoma, age, AIDS, alcohol consumption measurement, alcohol drinking, ...) of allowed values.insoluble-soluble fiber ratio, Confounders controlled for: "water intake [mL/day]" is not in the list (abnormal glucose tolerance, acetaldehyde, acute graft vs. host disease, acute lymphoblastic leukemia, acute myeloid leukemia, adenoma, age, AIDS, alcohol consumption measurement, alcohol drinking, ...) of allowed values.water intake [mL/day], Confounders controlled for: "coffee intake" is not in the list (abnormal glucose tolerance, acetaldehyde, acute graft vs. host disease, acute lymphoblastic leukemia, acute myeloid leukemia, adenoma, age, AIDS, alcohol consumption measurement, alcohol drinking, ...) of allowed values.coffee intake
Alpha Diversity
- Chao1 Abundance-based estimator of species richness
- increased
- Richness Number of species
- increased
Signature 1
Reviewed Marked as Reviewed by Atrayees on 2023-7-13
Source: Supplementary table 3
Description: Analysis of relative taxa abundance in controls and different disease groups.
Abundance in Group 1: increased abundance in patients with MSA(multiple system atrophy) disease
Signature 2
Reviewed Marked as Reviewed by Atrayees on 2023-7-13
Source: Supplementary table 3
Description: Analysis of relative taxa abundance in controls and different disease groups.
Abundance in Group 1: decreased abundance in patients with MSA(multiple system atrophy) disease
| NCBI | Quality Control | Links |
|---|---|---|
| Faecalibacterium | ||
| Prevotellaceae | ||
| Bacillota | ||
| Roseburia | ||
| Lachnospiraceae |
Experiment 4
Reviewed Marked as Reviewed by Atrayees on 2023-7-13
Differences from previous experiment shown
Subjects
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- patients with PSP(progressive supranuclear palsy) disease
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients diagnosed with tauopathy progressive supranuclear palsy (PSP)
Lab analysis
Statistical Analysis
Alpha Diversity
- Chao1 Abundance-based estimator of species richness
- increased
- Richness Number of species
- increased
Signature 1
Reviewed Marked as Reviewed by Atrayees on 2023-7-13
Source: Supplementary table 3, Signature 1 is for increased abundance in those with PSP
Description: Analysis of relative taxa abundance in controls and different disease groups
Abundance in Group 1: increased abundance in patients with PSP(progressive supranuclear palsy) disease
| NCBI | Quality Control | Links |
|---|---|---|
| Akkermansia | ||
| Christensenellaceae | ||
| Oscillospira | ||
| Verrucomicrobiota | ||
| Verrucomicrobiaceae | ||
| Pseudomonadota | ||
| Enterobacteriaceae |
Signature 2
Reviewed Marked as Reviewed by Atrayees on 2023-7-13
Source: Supplementary table 3
Description: Analysis of relative taxa abundance in controls and different disease groups
Abundance in Group 1: decreased abundance in patients with PSP(progressive supranuclear palsy) disease
| NCBI | Quality Control | Links |
|---|---|---|
| Lachnospiraceae | ||
| Roseburia | ||
| Streptococcaceae | ||
| Streptococcus | ||
| Prevotella | ||
| Faecalibacterium |
Experiment 5
Reviewed Marked as Reviewed by Atrayees on 2023-7-13
Differences from previous experiment shown
Subjects
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- patients with De-novo Parkinson's disease
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients with de novo Parkinson's disease with stage diagnosed according to UK Brain Bank Criteria(1996)
- Group 1 sample size Number of subjects in the case (exposed) group
- 39
Lab analysis
Statistical Analysis
- Confounders controlled for Confounding factors that have been accounted for by stratification or model adjustment
- age, alcohol drinking, breast feeding, sex, smoking status, constipation, Confounders controlled for: "use of catechol-O-methyltransferase inhibitors" is not in the list (abnormal glucose tolerance, acetaldehyde, acute graft vs. host disease, acute lymphoblastic leukemia, acute myeloid leukemia, adenoma, age, AIDS, alcohol consumption measurement, alcohol drinking, ...) of allowed values.use of catechol-O-methyltransferase inhibitors, Confounders controlled for: "genetic status (recessive)" is not in the list (abnormal glucose tolerance, acetaldehyde, acute graft vs. host disease, acute lymphoblastic leukemia, acute myeloid leukemia, adenoma, age, AIDS, alcohol consumption measurement, alcohol drinking, ...) of allowed values.genetic status (recessive), Confounders controlled for: "protein intake" is not in the list (abnormal glucose tolerance, acetaldehyde, acute graft vs. host disease, acute lymphoblastic leukemia, acute myeloid leukemia, adenoma, age, AIDS, alcohol consumption measurement, alcohol drinking, ...) of allowed values.protein intake, Confounders controlled for: "animal vegetal protein ratio" is not in the list (abnormal glucose tolerance, acetaldehyde, acute graft vs. host disease, acute lymphoblastic leukemia, acute myeloid leukemia, adenoma, age, AIDS, alcohol consumption measurement, alcohol drinking, ...) of allowed values.animal vegetal protein ratio, Confounders controlled for: "fibers intake" is not in the list (abnormal glucose tolerance, acetaldehyde, acute graft vs. host disease, acute lymphoblastic leukemia, acute myeloid leukemia, adenoma, age, AIDS, alcohol consumption measurement, alcohol drinking, ...) of allowed values.fibers intake, Confounders controlled for: "insoluble-soluble fiber ratio" is not in the list (abnormal glucose tolerance, acetaldehyde, acute graft vs. host disease, acute lymphoblastic leukemia, acute myeloid leukemia, adenoma, age, AIDS, alcohol consumption measurement, alcohol drinking, ...) of allowed values.insoluble-soluble fiber ratio, Confounders controlled for: "water intake [mL/day]" is not in the list (abnormal glucose tolerance, acetaldehyde, acute graft vs. host disease, acute lymphoblastic leukemia, acute myeloid leukemia, adenoma, age, AIDS, alcohol consumption measurement, alcohol drinking, ...) of allowed values.water intake [mL/day], Confounders controlled for: "coffee intake" is not in the list (abnormal glucose tolerance, acetaldehyde, acute graft vs. host disease, acute lymphoblastic leukemia, acute myeloid leukemia, adenoma, age, AIDS, alcohol consumption measurement, alcohol drinking, ...) of allowed values.coffee intake, Confounders controlled for: "use of protein pump inhibitors" is not in the list (abnormal glucose tolerance, acetaldehyde, acute graft vs. host disease, acute lymphoblastic leukemia, acute myeloid leukemia, adenoma, age, AIDS, alcohol consumption measurement, alcohol drinking, ...) of allowed values.use of protein pump inhibitors
Signature 1
Reviewed Marked as Reviewed by Atrayees on 2023-7-13
Source: Supplementary table 4
Description: Analysis of relative taxa abundance in different groups of Parkinson’s disease patients.
Abundance in Group 1: decreased abundance in patients with De-novo Parkinson's disease
| NCBI | Quality Control | Links |
|---|---|---|
| Lachnospiraceae |
Experiment 6
Reviewed Marked as Reviewed by Atrayees on 2023-7-13
Differences from previous experiment shown
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- healthy controls without any form of Parkinson's disease
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- patients with early Parkinson's disease
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients with early Parkinson's disease with stage diagnosed according to UK Brain Bank Criteria(1996)
- Group 1 sample size Number of subjects in the case (exposed) group
- 57
Lab analysis
Statistical Analysis
Signature 1
Reviewed Marked as Reviewed by Atrayees on 2023-7-13
Source: Supplementary table 4, Signature 1 is for increased taxa abundance among patients with early Parkinson's
Description: Analysis of relative taxa abundance in different groups of Parkinson’s disease patients
Abundance in Group 1: increased abundance in patients with early Parkinson's disease
| NCBI | Quality Control | Links |
|---|---|---|
| Akkermansia | ||
| Christensenellaceae | ||
| Enterobacteriaceae | ||
| Verrucomicrobiota | ||
| Verrucomicrobiaceae | ||
| Pseudomonadota | ||
| Oscillospira |
Signature 2
Reviewed Marked as Reviewed by Atrayees on 2023-7-13
Source: Supplementary table 4, Signature 2 is for decreased taxa abundance among participants with early Parkinson's
Description: Analysis of relative taxa abundance in different groups of Parkinson’s disease patients.
Abundance in Group 1: decreased abundance in patients with early Parkinson's disease
| NCBI | Quality Control | Links |
|---|---|---|
| Lachnospiraceae | ||
| Faecalibacterium | ||
| Bacillota | ||
| Roseburia |
Experiment 7
Reviewed Marked as Reviewed by Atrayees on 2023-7-13
Differences from previous experiment shown
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- healthy controls without any form of Parkinson's Disease
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- patients with mid stage Parkinson's
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients with mid stage Parkinson's disease with stage diagnosed according to UK Brain Bank Criteria(1996)
- Group 1 sample size Number of subjects in the case (exposed) group
- 53
Lab analysis
Statistical Analysis
Signature 1
Reviewed Marked as Reviewed by Atrayees on 2023-7-13
Source: Supplementary table 4
Description: Analysis of relative taxa abundance in different groups of Parkinson’s disease patients
Abundance in Group 1: increased abundance in patients with mid stage Parkinson's
| NCBI | Quality Control | Links |
|---|---|---|
| Akkermansia | ||
| Christensenellaceae | ||
| Enterobacteriaceae | ||
| Pseudomonadota | ||
| Verrucomicrobiota | ||
| Verrucomicrobiaceae | ||
| Bifidobacterium | ||
| Bifidobacteriaceae | ||
| Porphyromonadaceae | ||
| Parabacteroides |
Signature 2
Reviewed Marked as Reviewed by Atrayees on 2023-7-13
Source: Supplementary table 4
Description: Analysis of relative taxa abundance in different groups of Parkinson’s disease patients
Abundance in Group 1: decreased abundance in patients with mid stage Parkinson's
| NCBI | Quality Control | Links |
|---|---|---|
| Lachnospiraceae | ||
| Bacillota | ||
| Roseburia | ||
| Oscillospiraceae | ||
| Faecalibacterium |
Experiment 8
Reviewed Marked as Reviewed by Atrayees on 2023-7-13
Differences from previous experiment shown
Subjects
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- patients with advanced stage Parkinson's
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients with advanced stage Parkinson's disease with stage diagnosed according to UK Brain Bank Criteria(1996)
- Group 1 sample size Number of subjects in the case (exposed) group
- 44
Lab analysis
Statistical Analysis
Signature 1
Reviewed Marked as Reviewed by Atrayees on 2023-7-13
Source: Supplementary table 4, Signature 1 is for increased taxa abundance among those with advanced Parkinson's
Description: Analysis of relative taxa abundance in different groups of Parkinson’s disease patients
Abundance in Group 1: increased abundance in patients with advanced stage Parkinson's
Signature 2
Reviewed Marked as Reviewed by Atrayees on 2023-7-13
Source: Supplementary table 4, Signature 2 is for decreased taxa abundance among those with advanced Parkinson's
Description: Analysis of relative taxa abundance in different groups of Parkinson’s disease patients
Abundance in Group 1: decreased abundance in patients with advanced stage Parkinson's
| NCBI | Quality Control | Links |
|---|---|---|
| Bacillota | ||
| Lachnospiraceae | ||
| Faecalibacterium | ||
| Roseburia | ||
| Oscillospiraceae |
Retrieved from "https://bugsigdb.org/w/index.php?title=Study_537&oldid=82460"
